HAIFA, Israel, Dec. 19, 2024 (GLOBE NEWSWIRE) -- Pluri Inc. (Nasdaq: PLUR) (TASE: PLUR) ("Pluri" or the “Company"), an innovator in the development of leading cell-based technologies for various indications, congratulates Mesoblast Ltd. (“Mesoblast”) and its Chief Executive Officer, Silviu Itescu, on the U.S. Food and Drug Administration (the “FDA”) approval of the first MSC-based therapy for steroid-refractory acute graft-versus-host disease (“SR-aGVHD”). This landmark achievement marks a pivotal moment in ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Nevada 98-0351734 (State or other jurisdiction of incorporation or organization) (I.R.S. Employer Identification No.) Title of each class Trading Symbol Name of each exchange on which registered Common Shares, par value $0.00001 PLUR The Nasdaq Capital Market Form 10-Q (Mark One) ☒ QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 ☐ TRANSITION REPORT UNDER ...

Memorandum of Understanding has been signedNEW YORK, Nov. 11, 2024 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of cellular therapies for neurodegenerative diseases, today announced that it has entered into a Memorandum of Understanding (MOU) with Pluri Inc. (NASDAQ: PLUR) through its wholly owned subsidiary ("Pluri"), an established global leader in the development and manufacturing of cell-based therapeutics, to manufacture NurOwn® for use in BrainStorm's planned P ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended June 30, 2024 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from [ ] to [ ] Commission file number 001-31392 | --- | --- | |---------------------------------------------------------------------------------|----------------------------- ...

Vancouver, British Columbia--(Newsfile Corp. - July 23, 2024) - Purilock Security Inc. (TSXV: PLUR) (OTCQB: PLCKF) ("Plurilock" or the "Company"), a global cybersecurity services and solutions provider, announces a corporate update. When: Tuesday July 23, 2024, at 1pm ET / 10am PT Further to unlocking more value with existing clients, Plurilock is also focused on new customer acquisition (through hiring new sales staff) and identifying further opportunities to broaden its portfolio. On June 26, 2024, the Co ...

HAIFA, Israel, July 18, 2024 (GLOBE NEWSWIRE) -- Leading biotechnology company Pluri Inc. (NASDAQ:PLUR) (TASE:PLUR) ("Pluri" or the "Company"), which transforms cells into solutions that promote global wellbeing and sustainability, today announced it has signed a tech transfer and manufacturing agreement with Kadimastem Ltd. (TASE: KDST), a clinical stage biotechnology company developing therapeutic cells for ALS and diabetes treatments. PluriCDMO™, launched earlier this year, leverages Pluri's 47,000 squar ...

Company Overview - Pluri Inc is a leading biotechnology company that transforms cells into solutions promoting global wellbeing and sustainability [1] - The company operates in regenerative medicine, foodtech, and agtech, and offers CDMO services [7] - Pluri's proprietary 3D cell expansion technology is patented, scalable, cost-effective, and consistent [7] Strategic Collaboration - Pluri has entered a proof of concept agreement with a leading international agriculture corporation to boost global vegetable supply, streamline supply chains, and combat climate change [1] - The collaboration leverages Pluri's expertise in cell-expansion technologies and cellular agriculture, combined with the partner's global presence and knowledge of the food industry [10] - The partnership aims to minimize environmental impact, foster food security, and build sustainable, high-quality agricultural solutions [5] Market Context - The global vegetable farming market is valued at $1.3 trillion and is expected to grow to $1.6 trillion by 2029, with a CAGR of 3.4% from 2024 to 2029 [6] - The global population is projected to increase from 7.5 billion to 8.6 billion by 2030 and 11.2 billion by the end of the century, driving the need for alternative agricultural technologies [2] Business Strategy - Pluri's strategy involves collaborating with leading global companies across industries to generate revenue through innovative projects [2] - The company believes this collaboration has the potential to positively impact the vegetable market and create significant shareholder value [2] Technology and Innovation - Pluri's 3D cell expansion technology is expected to benefit farmers worldwide by enabling sustainable, high-quality agricultural solutions [5] - The company is pioneering a biotech revolution to address challenges in medicine, climate change, food scarcity, and animal cruelty [7]

"Ever After Foods' unique and innovative production platform empowered the change to our business model. The shift to a technology enabler will allow us to serve more players in the value chain," said Eyal Rosenthal, Chief Executive Officer of Ever After Foods."Securing funding from new global partners is a testament to our team's tireless dedication to solving the primary production barriers for the next step toward a more sustainable meat industry. In addition to the funding, working with new partners in ...

"The joint investment by global multinational companies, along with Tnuva and Pluri, in Ever After Foods' unique technology platform, its team, and vision underscores the critical role of collaboration in ensuring a sustainable and secure global food system," noted Haim Gavrieli, Tnuva's Chairman of the Board. "The way the world produces and consumes meat will significantly change over the next decade, bringing many opportunities for cultivated meat players. As the leading alternative protein group in Israe ...

As part of Pluri's previously announced $4.2 million 3-year contract with the U.S. National Institute of Allergy and Infectious Diseases (NIAID), the option for the second year of the contract has been exercised to fund manufacturing, in-vitro, and in-vivo studies of Pluri's cell therapy PLX-R18 is designed to be a first in class, effective treatment for ionizing radiation injuries that could be anticipated in the wake of a large-scale nuclear incident Work during the contract period is expected to make fur ...